<ul>
<li>Savara highlighted Phase 3 IMPALA-2 data for MOLBREEVI (molgramostim inhalation solution) in autoimmune pulmonary alveolar proteinosis, showing a statistically significant improvement in the primary endpoint of change in DLCO% at Week 24 versus placebo (p=0.0007).     *      DLCO% gains were sustained at Week 48, with a statistically significant between-group difference versus placebo (p=0.0008).     *      Patient-reported outcomes improved at Week 24, with a statistically significant reduction in SGRQ Total Score versus placebo (p=0.0072), while Week 48 did not reach statistical significance (p=0.1046).     *      The presentation set an FDA BLA PDUFA date of Nov. 22, 2026 for MOLBREEVI, which remains unapproved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

SVRA

LABU

SBIO

<p>Savara's corporate presentation highlighted Phase 3 IMPALA-2 data for MOLBREEVI, showing significant improvement in DLCO% at Week 24 and sustained gains at Week 48 versus placebo. Patient-reported outcomes also improved at Week 24. The FDA BLA PDUFA date for MOLBREEVI is set for Nov. 22, 2026, with the drug still unapproved.</p>

PUBT

Savara

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program